It is very uncertain whether piperacillin changes all‐cause mortality maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin changes serious adverse events maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin changes nephrotoxicity maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes serious adverse events maximum compared with amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with piperacillin plus gentamicin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with piperacillin plus gentamicin (very low certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.